Fig. 3: Percentage of participants with ≥4-fold increase in levels of S. sonnei LPS fecal sIgA and S. sonnei LPS specific IgG/IgA levels from α4β7+ and α4β7− ASCs. | npj Vaccines

Fig. 3: Percentage of participants with ≥4-fold increase in levels of S. sonnei LPS fecal sIgA and S. sonnei LPS specific IgG/IgA levels from α4β7+ and α4β7− ASCs.

From: Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine

Fig. 3

Bar graph showing from (a) to (e), S.sonnei fecal sIgA (a); S.sonnei LPS specific IgG from α4β7+ ASCs (b); S.sonnei LPS specific IgG from α4β7− ASCs (c); S.sonnei LPS specific IgA from α4β7+ ASCs (d); and S.sonnei LPS specific IgA from α4β7− ASCs (e). The 1790GAHB group shows a higher percentage of participants (represented by higher bars) achieving a 4-fold increase or more from baseline for all the parameters, at both Day 8 and Day 36, except for fecal IgA which was similar between recipients of 1790GAHB and placebo at both timepoints. The 95% confidence intervals are represented by the vertical overlay error bars in each case.

Back to article page